Can-Fite BioPharma vs SciSparc
CANF and SPRC side by side, both in drugs. Figures are trailing twelve months unless noted, from SEC filings and end-of-day prices.
How CANF and SPRC compare
SciSparc grew revenue faster over the last twelve months (−34.5% versus −39.9% for Can-Fite BioPharma).
SciSparc keeps more of each dollar of sales as profit, with a net margin of −1423% compared with −2427% at Can-Fite BioPharma.
SciSparc scores higher on the StockData Score (3 against 1 for Can-Fite BioPharma), which adds up 30 checks on valuation, growth, past performance, financial health and dividends.
Key numbers
A dot marks the better figure where higher or lower is clearly better.
| Metric | CANF | SPRC |
|---|---|---|
| Size and price | ||
| Share price | $1.49 | $0.355 |
| Change, 1 year | −81.2% | −98.6% |
| Change, 5 years | −99.4% | −100.0% |
| Beta (5Y) | 1.10 | 0.30 |
| Employees | 5 | 3 |
| StockData Score | ||
| Total score | 1 | 3 (better) |
| Valuation score | 0 | 0 |
| Growth score | 0 | 1 (better) |
| Performance score | 0 | 0 |
| Health score | 1 | 2 (better) |
| Dividend score | 0 | 0 |
| Growth | ||
| Revenue growth (TTM) | −39.9% | −34.5% (better) |
| Revenue growth, 5Y average | −11.9% | – |
| EPS growth (TTM) | – | −51.9% |
| EPS growth, 5Y average | – | 36.4% |
| Profitability | ||
| Gross margin | – | 73.7% |
| Operating margin | −2457% | −978% (better) |
| Net margin | −2427% | −1423% (better) |
| FCF margin | −2210% | – |
| Return on equity | −217% (better) | −770% |
| Financial health | ||
| Debt / equity | – | 0.09 |
| Interest coverage | −35.0× | −1.0× (better) |
| Current ratio | 3.60 (better) | 0.87 |
| Piotroski F-score | 2 | 3 (better) |
| Ownership | ||
| Held by institutions | 1.9% | – |
| Held by insiders | 0.00% | 15.6% |
| Insider net buying, 12 months | – | −$4.6K |
| Short interest, % of float | – | 22.5% |
Go deeper
- CANF stock overview
- CANF income statement
- CANF valuation and score
- SPRC stock overview
- SPRC income statement
- SPRC valuation and score
For information only, not investment advice. Check the source filings before relying on any figure.